Ambu A/S
Abonner på pressemeddelelser fra Ambu A/S
Abonner på alle pressemeddelelser fra Ambu A/S ved at registrere din e-mail nedenfor. Det er ligeså let at melde fra igen.
Anders HjortHead of Investor Relations
Tlf:+45 2892 8881anhj@ambu.comTine Bjørn SchmidtHead of Corporate Communications
Tlf:+45 2264 0697tisc@ambu.comSince 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in Europe, North America, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
- Ambu A/S
- Baltorpbakken 13
- 2750 Ballerup
- +45 7225 2000
- www.ambu.com
Selskabsmeddelelser
13
MenuReporting of transactions made by persons discharging managerial responsibilities22.11.2024 16:01:18 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Company announcement no. 7 2024-2025
2 vedhæftninger
Reporting of transactions made by persons dischargingmanagerial responsibilities22.11.2024 16:00:00 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Company announcement no. 6 2024-2025
2 vedhæftninger
NOTICE OF THE ANNUAL GENERAL MEETING 2024 OF AMBU A/S8.11.2024 12:15:29 CET | Ambu A/S | Notice to general meeting
Notice is hereby given of the annual general meeting of Ambu A/S, CVR no. 63 64 49 19, which is held on Wednesday, 4 December 2024 at 1:00 pm (CET) at the company’s address at Baltorpbakken 13, 2750 Ballerup. Board of Directors The Board of Directors proposes re-election of Jørgen Jensen as Chair of the Board and Shacey Petrovic as Vice Chair. The Board of Directors proposes that Susanne Larsson, Michael del Prado and Simon Hesse Hoffmann are all re-elected. Furthermore, the Board of Directors proposes that David Hale be elected as a new member to the Board of Directors. Christian Sagild has decided not to run for re-election. The notice for this year’s annual general meeting, including information about the proposed Board candidates, is enclosed. This notice is available in Danish and English-language versions. In the event of discrepancies, the English version shall prevail. Ambu A/S offers the possibility of viewing the annual general meeting 2024 via live webcast on Ambu’s website.
3 vedhæftninger
Reporting of transactions made by persons discharging managerial responsibilities7.11.2024 16:44:22 CET | Ambu A/S | Managers' Transactions
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares.
2 vedhæftninger
ANNUAL REPORT 2023/245.11.2024 07:00:00 CET | Ambu A/S | Annual Financial Report
Today, Ambu releases its annual report for the 2023/24 financial year. For the full year, Ambu reported 13.8% organic revenue growth. This was driven by Endoscopy Solutions growing 19.7% and Anaesthesia & Patient Monitoring growing 6.1%. Moreover, Ambu’s EBIT margin before special items reached 12.0%, and the company’s free cash flow before acquisitions totalled DKK 524m. The financial outlook for the 2024/25 financial year is set as follows: 10-13% organic revenue growth and 12-14% reported EBIT margin before special items. In addition, Ambu’s free cash flow expectations (before acquisitions) are set to DKK +500m, and Endoscopy Solutions growth is expected to reach +15%, driven by continued momentum across all endoscopy segments. "I am incredibly proud of our achievements this year. On our transformation journey, we have made significant progress, returning to double-digit growth and expanding our endoscopy solutions offering for healthcare professionals in urology, pulmonology and ga
6 vedhæftninger
INTERIM REPORT FOR Q4 AND THE FULL-YEAR 2023/24 RESULTS (UNAUDITED)4.11.2024 18:15:27 CET | Ambu A/S | Inside information
In the fourth quarter of the 2023/24 financial year, Ambu delivered 10.6% organic revenue growth and a 10.6% EBIT margin before special items, driven by Endoscopy Solutions growing 14.5% and Anaesthesia & Patient Monitoring growing 5.3%. This brings the full-year 2023/24 Group organic growth to 13.8% and the EBIT margin b.s.i. to 12.0%. Endoscopy Solutions sustained strong momentum throughout the year, achieving 19.7% organic growth for the full year. Also, new regulatory clearances were secured in both urology and GI during the year. Today, 4 November 2024, Ambu sets the financial guidance for 2024/25, with organic revenue growth of 10-13% and EBIT margin before special items of 12-14%. In addition, expectations for free cash flow before acquisitions are set to DKK +500m. This guidance assumes continued momentum across all endoscopy segments, reflected by +15% expected growth in Endoscopy Solutions. “In the fourth quarter, Ambu delivered solid growth and profitability, proving we ar
2 vedhæftninger
AMBU ANNOUNCES FINANCIAL OUTLOOK FOR THE 2024/25 FINANCIAL YEAR4.11.2024 18:02:41 CET | Ambu A/S | Inside information
Today, Ambu A/S is pleased to announce the Company’s financial outlook for the 2024/25 financial year.
2 vedhæftninger
AMBU FINANCIAL CALENDAR FOR 2024/2530.9.2024 13:08:29 CEST | Ambu A/S | Financial Calendar
This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2024/25, as well as the date of Ambu’s annual general meeting. 2024 5 November 2024 Annual report 2023/24 4 December 2024 Annual general meeting 2025 30 January 2025 Earnings release Q1 2024/25 7 May 2025 Earnings release Q2 2024/25 22 August 2025 Earnings release Q3 2024/25 30 September 2025 End of fiscal year 2024/25 5 November 2025 Annual report 2024/25 3 December 2025 Annual general meeting Deadline for the inclusion of specific items on the agenda for the annual general meeting 2024 is 22 October 2024.
2 vedhæftninger
Major shareholder announcements2.9.2024 12:17:06 CEST | Ambu A/S | Major shareholder announcements
With reference to Section 30 of the Danish Capital Markets Act, Ambu A/S hereby announces that on 2 September 2024, Ambu has received three separate major shareholder notifications regarding voting rights attached to A-shares in Ambu A/S from: Inga Hesse Kovstrup, Pia Hesse, and Eva Hesse Lundström. The three major shareholder announcements are published as appendices to this company announcement.
5 vedhæftninger
INTERIM REPORT FOR Q3 2023/2430.8.2024 07:00:00 CEST | Ambu A/S | Interim report (Q1 and Q3)
In the third quarter of the 2023/24 financial year, Ambu delivered 15.0% organic revenue growth and a 12.9% EBIT margin before special items. This was driven by Endoscopy Solutions growing 18.0% and Anaesthesia & Patient Monitoring growing 10.9%. On July 10, 2024, Ambu raised its financial guidance by upgrading its full-year organic revenue growth to 12-14%, from 10-12%, and EBIT margin before special items to 11-13%, from 10-12%. In addition, the company raised its free cash flow expectations to DKK +450m, from DKK +370m. The better-than-expected performance was driven by continued strong growth in Endoscopy Solutions, solid growth in Anaesthesia & Patient Monitoring and improved operational leverage, in line with Ambu’s ZOOM IN strategy and transformation plan. “I am proud to see that in Q3, our global teams continued our strong growth momentum, achieving double-digit growth in both Endoscopy Solutions and Anaesthesia & Patient Monitoring, while also securing an improved profitabilit
2 vedhæftninger
AMBU INCREASES FINANCIAL OUTLOOK FOR THE 2023/24 FINANCIAL YEAR10.7.2024 19:33:44 CEST | Ambu A/S | Inside information
Today, Ambu announces preliminary Q3 2023/24 results and upgrades its expectations for the full financial year 2023/24. Due to better-than-expected performance in Q3, Ambu increases its financial outlook for organic revenue growth to 12-14% (previously 10-12%) and for EBIT margin before special items to 11-13% (previously 10-12%). The better-than-expected performance is driven by continued strong growth in Endoscopy Solutions, solid growth in Anaesthesia & Patient Monitoring and improved operational leverage, in line with Ambu’s transformation plan. In addition, the company raises its free cash flow expectations to DKK +450m (previously DKK +370m). PRELIMINARY AND UNAUDITED FINANCIAL HIGHLIGHTS FOR Q3 2023/24 Last year’s comparative figures are stated in brackets. Revenue was DKK 1,383m (DKK 1,195m), with organic revenue growth of 15.0% (8.1%), driven by continued strong growth in Endoscopy Solutions and solid growth in Anaesthesia & Patient Monitoring. Reported growth for the quarter
2 vedhæftninger
INTERIM REPORT FOR Q2 2023/24 AND THE HALF-YEAR14.5.2024 07:00:01 CEST | Ambu A/S | Half Year financial report
In the second quarter of the 2023/24 financial year, Ambu delivered 15.5% organic revenue growth and a 14.2% EBIT margin before special items. This was driven by Endoscopy Solutions growing 22.3% and Anaesthesia & Patient Monitoring growing 7.0%. On April 10, 2024, Ambu raised its financial guidance by upgrading its full-year organic revenue growth to 10-12% from 7-10% and EBIT margin before special items to 10-12% from 8-10%. In addition, the company raised its free cash flow expectations to DKK +370m from DKK +270m. This was mainly driven by better-than-expected outcomes of contract negotiations in Anaesthesia & Patient Monitoring. “I am pleased with the performance within the second quarter of our fiscal year 2023/24, where our Endoscopy Solutions business delivered 22.3% organic revenue growth, and we improved both our profitability and free cash flow, slightly ahead of our ongoing transformation to deliver profitable growth. Our Endoscopy Solutions business grew in all segments, a
2 vedhæftninger
AMBU RAISES OUTLOOK FOR THE 2023/24 FINANCIAL YEAR10.4.2024 21:27:06 CEST | Ambu A/S | Inside information
Today, Ambu announces preliminary results for the first half-year of 2023/24 and adjusts its expectations for the full financial year 2023/24. As a result of solid financial performance year-to-date and expected continued momentum in revenue growth, Ambu increases its financial outlook for organic revenue growth to 10-12% (previously 7-10%) and for EBIT margin before special items to 10-12% (previously 8-10%). In addition, the company raises its free cash flow expectations to DKK +370m (previously DKK +270m). The raised outlook is mainly driven by better-than-expected outcomes of contract negotiations in Anaesthesia & Patient Monitoring, strong organic growth in Endoscopy Solutions and continued strengthened operational leverage. PRELIMINARY AND UNAUDITED FINANCIAL HIGHLIGHTS FOR Q2 2023/24 Last year’s comparative figures are stated in brackets. Revenue was DKK 1,367m (DKK 1,189m), with organic revenue growth of 15.5% (4.2%). Reported growth for the quarter was 15.0% (6.0%). Year-to-da
2 vedhæftninger
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in Europe, North America, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
- Ambu A/S
- Baltorpbakken 13
- 2750 Ballerup
- +45 7225 2000
- www.ambu.com